Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma

Exclusion Criteria

• •History of cardiac disease: congestive heart failure \> New York Heart Association (NYHA) class 2; active coronary artery disease (CAD); cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin), or uncontrolled hypertension. Myocardial infarction more than 6 months prior to study entry is permitted.
• •Abnormalities of the cornea based on history (e.g. dry eye syndrome, Sogren's syndrome) including congenital abnormality (e.g. Fuch's dystrophy), abnormal slit-lamp examination using a vital dye (e.g. fluorescein, Bengal-Rose), and/or an abnormal corneal sensitivity test (Schirmer test or similar tear production test).
• •History of interstitial lung disease (ILD).
• •Patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry.
• •Previous treatment with yttrium-90 spheres
• •Any condition that is unstable or which could jeopardize the safety of the patient and his/her compliance in the study.
• •Uncontrolled ascites (defined as not easily controlled with diuretic treatment)